Anixa is focused on harnessing the bodyâs immune system in the fight against cancer. Anixaâs therapeutics portfolio includes a cancer immunotherapy program, which uses chimeric endocrine receptor t-cell (CER-T) technology, a novel type of CAR-T, and a cancer vaccine technology focused specifically on triple negative breast cancer (TNBC), the most lethal form of the disease. Anixaâs diagnostics portfolio includes the CchekTM liquid biopsy technology, a series of inexpensive non-invasive blood tests for early detection of solid tumors based on the bodyâs immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Source
No articles found.
Phio Pharmaceuticals is focused on developing the next generation of immuno-oncolo...
Phio Pharmaceuticals is focused on developing t...
Acasti is a biopharmaceutical innovator focused on the research, development and c...
Acasti is a biopharmaceutical innovator focused...
vTv Therapeutics is a clinical-stage biopharmaceutical company engaged in the disc...
vTv Therapeutics is a clinical-stage biopharmac...
SI-BONE is a medical device company that has pioneered a proprietary minimally inv...
SI-BONE is a medical device company that has pi...
Join the National Investor Network and get the latest information with your interests in mind.